Rezolute Bio
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us
  • Therapeutic Focus
    • Pipeline
    • RZ358
    • RZ402
    • Publications
    • Data Presentations
  • For Patients
    • Overview
    • Living with HI
    • Living with DME
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Join Us
    • Our Mission
    • Open Positions
    • Benefits
  • Contact Us
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info

Press Releases

  • News & Events

  • Overview
  • IR Calendar
Dec 18, 2019 3:00pm EST

Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes

Dec 02, 2019 9:25am EST

Rezolute Management to Present at 2020 Biotech Showcase Conference

Nov 25, 2019 9:25am EST

Rezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors

Oct 11, 2019 4:24pm EDT

Rezolute Management to Present at 2019 BIO Investor Forum Conference

Aug 05, 2019 9:25am EDT

Rezolute Management to Present at 2019 Canaccord Genuity Growth Conference

Jul 24, 2019 9:25am EDT

Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option

Jan 07, 2019 8:39am EST

Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million

May 16, 2018 8:00am EDT

Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer

Apr 09, 2018 8:00am EDT

Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development

Apr 04, 2018 8:00am EDT

Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors

  • arrow_back
  • 1…
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
rezolute logo

©2023 Rezolute, Inc.

Explore

  • Therapeutic Focus
  • For Patients
  • About
  • Join Us
  • Contact Us
  • Investors & Media

Contact

Corporate Headquarters

275 Shoreline Drive
Suite 500
Redwood City, CA 94065
+1 (650) 206-4507
info@rezolutebio.com

Investor Relations

Investor Relations Contacts

Legal

  • Terms of Use
  • Privacy Policy
MENU
  • Therapeutic Focus
    • Pipeline
    • RZ358
    • RZ402
    • Publications
    • Data Presentations
  • For Patients
    • Overview
    • Living with HI
    • Living with DME
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Join Us
    • Our Mission
    • Open Positions
    • Benefits
  • Contact Us
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News & Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info